Articles
Click on the image to read the article on LinkedIn and join the conversation!
While we accept and support that there is a growing trend to reduce or eliminate animal studies for humane reasons, we must acknowledge that we cannot do so if it puts our patients in harm's way. So how do we get there safely, gaining the benefits of AI while not losing the breadth of information gained from animal toxicology studies?
Are we heading in the right direction?
The global landscape of drug development is intricate, relying on complex international supply chains, significant investment, and intricate regulatory pathways. Introducing tariffs, a tax on imported goods, into this delicate ecosystem could have far-reaching and potentially detrimental consequences for the discovery, production, and accessibility of life-saving medicines.
How do we prepare?
In the highly competitive pharmaceutical industry, small companies face a unique set of challenges when developing new drugs. While these organizations often drive the majority of innovation and bring fresh approaches to treating diseases, they must navigate a complex landscape with limited resources.
Can small biotechs overcome these hurdles?
NexusBio Partners believes the paradigm of drug discovery is shifting.
The next breakthrough may not originate in a lab, but from AI's ability, with the right data feeding into the large language model (LLM), to predict with unprecedented precision. While AI begins to transform drug development, it is incumbent upon drug developers to ensure its credibility and safety within the highly regulated pharmaceutical industry.
What do you think?
The biotechnology industry operates at the nexus of cutting-edge science, intricate regulatory frameworks, and rapidly shifting market dynamics. While innovation is the lifeblood of biotech, a company's success—whether it’s a startup developing a groundbreaking therapy or a large firm streamlining its operations—hinges on strategic decision-making.
Join the discussion on why consultants often make perfect short term sense and sometimes are a key part of a solid long term strategy.
Proper accounting and robust business processes are at least as critical, and perhaps even more critical for biotech startups and small biotech companies than for Fortune 500s.
Read why in this brief article!
We invite you to add your comments and join the conversation on LinkedIn.
Imagine a world where the delicate balance between medical innovation and public trust hangs by a thread. Now, place Robert F. Kennedy Jr. at the helm of the U.S. Department of Health and Human Services (HHS), where his leadership could have profound consequences, either guiding the US health system toward potentially better, but uncharted, waters or exacerbating existing and harmful divisions.
We invite you to read and comment on this article -- join the conversation on LinkedIn.
The BIOSECURE Act, passed by the US House in late 2024, has yet to be considered by the Senate. This leaves the bill's future uncertain and raises questions about its potential impact on the US pharmaceutical industry, particularly for startup, small, and emerging biotech companies.
We invite you to read and comment on this article -- join the conversation on LinkedIn.
Risk identification only works if everyone is truly engaged--not just participating, but engaged fully as if an owner of the activity.
Read how one healthcare expert managed to bring together a wide range of diverse, talented groups to quickly achieve a potentially complicated end goal.
Please feel free to watch, read, and join the conversation by posting comments on these contributions to the industry.